Orphan drugs: rising to the challenge to ensure a better future for 30 million patients in Europe

As the number of drugs for rare diseases grows, there is also growing concern that increasing costs will put an excessive strain on healthcare budgets. EURORDIS has released a paper, which uses mathematical models to predict the number of orphan drugs that will enter the market in the next ten years and their economic impact. The paper dispels the myth of a ’tidal wave’ of orphan drugs flooding the market and of their potential overwhelming cost to society.

 
 
The voice of rare disease patients in EuropeEURORDIS The international voice of people living with rare diseases, Rare Diseases International is a EURORDIS initiativeRare Disease International Bringing together patients, families and experts to share experiences in a moderated multilanguage forum, RareConnect is a EURORDIS initiative RareConnect An international awareness raising campaign taking place on the last day of February each year, Rare Disease Day is a EURORDIS initiativeRare Disease Day Join the largest gathering of rare disease stakeholders across Europe, at the biennial European Conference on Rare Diseases and Orphan Products. ECRD is a EURORDIS initiativeEuropean Conference on Rare Diseases